<DOC>
	<DOCNO>NCT01382602</DOCNO>
	<brief_summary>This clinical trial study safety effectiveness autologous muscle-derived cell ( AMDC ) treatment female stress urinary incontinence ( SUI ) .</brief_summary>
	<brief_title>Autologous Muscle-derived Cells Female Stress Urinary Incontinence Clinical Study</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence , Stress</mesh_term>
	<criteria>Female patient primary symptom SUI , confirm patient medical history clinical symptom , include focused incontinence evaluation . Patient symptoms pure urge incontinence confirm basic evaluation etiology patient medical history , include focused incontinence history . Patient symptom mixed urinary incontinence urge incontinence predominant factor . Patient stress urinary incontinence symptom less 6 month prior sign inform consent . Patient previously attempt conservative treatment least 1 month prior sign inform consent . ( Examples conservative treatment include behavior modification , bladder exercise , biofeedback , etc . ) Patient 2 episode awaken void normal sleeping hour . Patient maintain stable dose and/or frequency medication ( include diuretic ) know affect low urinary tract function , include limited , anticholinergic , tricyclic antidepressant alphaadrenergic blocker , least 2 week prior randomization likely change course study . Patient pregnant , lactate , plan become pregnant course study . Patient refuse provide write informed consent . Patient least 18 year age . Patient available followup evaluation require protocol .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Urinary Incontinence , Stress</keyword>
	<keyword>Tissue Therapy ( Cell Therapy )</keyword>
	<keyword>Transplantation , Autologous</keyword>
</DOC>